Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak.
about
A case of hemolytic uremic syndrome caused by Escherichia coli O104:H4Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeHaemolytic uraemic syndrome.The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients.Consanguineous hemolytic uremic syndrome secondary to Escherichia coli O157:H7 infection treated with aggressive therapeutic plasma exchange.Thrombotic microangiopathies in bone marrow and organ transplant patients.Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.Thrombotic microangiopathies: an update.Evaluation and management of patients with thrombotic thrombocytopenic purpura.Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison.Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.Thrombotic microangiopathy and associated renal disorders.Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.Renal and neurological involvement in typical Shiga toxin-associated HUS.Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.[Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak].Psychiatric symptoms in patients with Shiga toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome.A diagnosis of haemolytic-uraemic syndrome blurred by alcohol abuse.[After the crisis is before the crisis: Coping-strategies for public health emergency situations on different levels--experiences of the German E. coli outbreak 2011].Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).Three years experience of adults admitted to hospital in north-east Scotland with E. coli O157.Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coliBenefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism.Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience.Immune effect of heat-killed multistrain of Lactobacillus acidophilus against Salmonella typhimurium invasion to mice.Management of hemolytic uremic syndromeThrombotic thrombocytopenic purpuraHemolytic uremic syndrome
P2860
Q24654024-815DC5BA-E731-42B0-8B26-1D513943B7C8Q24685473-85BABCEA-A020-43A5-9DA5-E3CC9A0B4F55Q30244707-F1A367C8-B4D5-45B1-8D3B-CB5EFCA1BF8CQ33338745-678070DC-B7D0-48E2-8DDE-94D693AD75EFQ33340222-1D5A74D6-4D84-4BF6-A8F4-C7E00C22E7C5Q33344694-6A9DCAC9-D12C-42F7-9E4F-57F2B66B0086Q33346559-739C968D-7BD3-45CD-AA3F-7C97734B451AQ33374370-DCCC1464-0965-433B-81AC-413BC34E412CQ33375004-D743A829-3D68-4B38-9C3E-CB76E928BEB3Q33379319-8D3C471F-B2B7-4C6D-A2D8-977A7E0D4A0DQ33399130-27D6FEAF-3B3C-4F70-BFF0-23E1F2390671Q33402372-371D0826-2149-4ED8-8C78-0A54329F142CQ33402784-B267DF14-E587-4BBD-B22C-044FD4D5E8FBQ33403361-E0EAA479-E1E1-428C-AF29-7BA6E601006BQ33404149-0A1717B2-3984-457F-9EC4-664A4A5BB6ADQ33404151-60B84312-4F24-48A7-9052-07738D987964Q33404545-93A28EA1-6413-47D0-A966-EBD3CF0AB383Q33416354-E0D3F635-4A9C-4089-9BB3-C6A9590D9B7CQ33419491-6C7AC565-5320-48B4-A303-86AF47A16B55Q33424235-F759155E-DDDF-4D66-84B3-046311D1C828Q33424483-03688976-5F66-427F-88C8-F917442C3F69Q33431806-62B62FF9-F890-4DC0-8EA1-AF3C56F0EE51Q35018603-1DC858D4-1F4A-475C-8346-AC8CF6994A5BQ36563022-87E3B18C-C247-436D-AA05-791A80752804Q37820338-9AE426B0-FC70-473E-8633-92D690DC00E3Q41639218-587E0227-1702-4048-9E36-5F2C845B9328Q47588905-EA373DAC-3B0B-4E8C-8097-B5C756E18FA1Q50074809-F1214669-979A-4667-BA79-33AF814A3879Q57161996-F1CBF495-52FD-451A-A030-06342682634AQ57591162-8572F505-B1AD-446A-92C0-90C209932C56Q57701679-2F0C52DF-4CB4-4283-A845-D2C39B40B1BC
P2860
Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@ast
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@en
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@nl
type
label
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@ast
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@en
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@nl
prefLabel
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@ast
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@en
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@nl
P2093
P1433
P1476
Effectiveness of therapeutic p ...... erichia coli O157:H7 outbreak.
@en
P2093
P304
P356
10.1016/S0140-6736(99)01251-9
P407
P577
1999-10-01T00:00:00Z